Abstracts tagged "psoriatic arthritis and therapy"

Abstract Number: 3036 • 2016 ACR/ARHP Annual Meeting
IL-22 Is Dysregulated in Psoriatic Arthritis and Acts to Limit IFN-γ Driven Inflammatory Chemokine Production
Amara Ezeonyeji¹, Helen Baldwin², Milica Vukmanovic-Stejic³ and Michael R. Ehrenstein⁴, ¹Rheumatology, Medicine, University College London, London, United Kingdom, ²Rheumatology, Centre for Rheumatology Research, University College London, london, United Kingdom, ³Infection & Immunity, University College London, london, United Kingdom, ⁴Medicine, University College London, London, United Kingdom
Background/Purpose: IL-22 is an IL-10 family cytokine with both pro-inflammatory and anti-inflammatory effects and its dysregulation is associated with the development of autoimmune disease including…
Abstract Number: 2841 • 2015 ACR/ARHP Annual Meeting
Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Philip J. Mease¹, Tamara Lesperance², Neil Accortt², David Collier², Mei Liu³, Marc Mason⁴ and Sabrina Deveikis⁴, ¹Clinical Professor, University of Washington School of Medicine, Seattle, WA, ²Amgen, Inc., Thousand Oaks, CA, ³352 Turnpike Rd, Corrona, LLC, Southborough, MA, ⁴Corrona, LLC., Southborough, MA
Background/Purpose: Over the past decade, the treatment of PsA has improved significantly. The purpose of this study was to describe real-world treatment patterns among PsA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].